Bioengineered Pancreatic Cancer Immunosuppressive Microenvironment Models for Screening Immunotherapies
Source abstract
Abstract
ABSTRACT Pancreatic cancer is notably resistant to treatment, primarily due to its dense desmoplastic stroma and immunosuppressive microenvironment. Accurately modeling this complex landscape and its immunosuppressive hallmarks in vitro is highly valuable for screening immunotherapeutic strategies. However, replicating these intricate features remains a significant challenge. Herein, we bioengineered miniaturized tumor‐stroma platforms that combine cancer and stromal cells, as well as extracellular matrix mimetic biomaterials as a strategy to emulate the native tumor composition and key tumor immunosuppressive signatures. Bioengineered stratified tumor‐stroma pancreatic cancer models, so termed cancer‐on‐a‐bead platforms are generated in superhydrophobic surfaces and co‐cultured with T cells, dendritic cells, as well as M0 macrophages, as a strategy to recapitulate tumor‐immune interplay. The generated models revealed suppression of antigen presentation, M2 macrophage polarization, and T cell exhaustion, representing key features of this neoplasia. The screening of antibody mediated immunotherapy in the 3D tumor platforms, using clinically approved anti PD‐1 antibody as a model therapeutic, partially restored T cell function. Overall, our findings demonstrate compartmentalized tumor‐stroma models potential for being used to screen candidate immunotherapeutics for pancreatic cancer in a preclinical setting.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Cells and Metastasis · 3D Printing in Biomedical Research · Pancreatic and Hepatic Oncology Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry CICECO – Aveiro Institute of Materials University of Aveiro Campus Universitário de Santiago Aveiro Portugal
Cellularis Biomodels Pci Creative Science Park Aveiro Region Via do Conhecimento Edifício Central Ílhavo Portugal
Department of Medical Sciences and Institute of Biomedicine – iBiMED University of Aveiro Aveiro Portugal
References (51)
Show source-provided references
1. 10.1038/s43018-022-00349-210.1038/s43018-022-00349-2 ↗
2. 10.3390/cancers1608147010.3390/cancers16081470 ↗
3. 10.1016/j.biomaterials.2022.12165310.1016/j.biomaterials.2022.121653 ↗
4. 10.1038/s41419-022-05351-110.1038/s41419-022-05351-1 ↗
5. 10.1038/s41698-024-00681-z10.1038/s41698-024-00681-z ↗
6. 10.1007/s13402-022-00741-110.1007/s13402-022-00741-1 ↗
7. 10.1186/s13046-023-02935-310.1186/s13046-023-02935-3 ↗
8. 10.3390/cancers1404099510.3390/cancers14040995 ↗
9. 10.3389/fphar.2023.111337810.3389/fphar.2023.1113378 ↗
10. 10.3390/ijms2410870710.3390/ijms24108707 ↗
11. 10.1186/s12943-018-0815-z10.1186/s12943-018-0815-z ↗
12. 10.1186/s13045-017-0448-510.1186/s13045-017-0448-5 ↗
13. 10.7150/thno.2654610.7150/thno.26546 ↗
14. 10.3390/cancers1416399410.3390/cancers14163994 ↗
15. 10.1016/j.tibtech.2024.06.00810.1016/j.tibtech.2024.06.008 ↗
16. 10.1021/acs.biomac.4c0181610.1021/acs.biomac.4c01816 ↗
17. 10.1002/smtd.20200120710.1002/smtd.202001207 ↗
18. 10.1002/adhm.20210257410.1002/adhm.202102574 ↗
19. 10.1021/acsami.4c1118810.1021/acsami.4c11188 ↗
20. 10.1186/s40169-019-0226-910.1186/s40169-019-0226-9 ↗
21. 10.1038/s41388-019-0765-y10.1038/s41388-019-0765-y ↗
22. 10.1016/j.actbio.2016.11.07210.1016/j.actbio.2016.11.072 ↗
23. 10.1158/0008-5472.CAN-04-067710.1158/0008-5472.CAN-04-0677 ↗
24. 10.1158/1078-0432.CCR-13-052510.1158/1078-0432.CCR-13-0525 ↗
25. 10.1158/1078-0432.CCR-16-087010.1158/1078-0432.CCR-16-0870 ↗
26. 10.1016/S1470-2045(16)00078-410.1016/S1470-2045(16)00078-4 ↗
27. 10.1158/1078-0432.CCR-15-041610.1158/1078-0432.CCR-15-0416 ↗
28. 10.3389/fonc.2020.57639910.3389/fonc.2020.576399 ↗
29. 10.1016/j.bbcan.2023.18906510.1016/j.bbcan.2023.189065 ↗
30. 10.3390/cancers1105072110.3390/cancers11050721 ↗
31. 10.7554/eLife.6264510.7554/eLife.62645 ↗
32. 10.1186/s12967-025-07164-010.1186/s12967-025-07164-0 ↗
33. 10.1186/s13045-025-01717-y10.1186/s13045-025-01717-y ↗
34. 10.3389/fimmu.2017.0151410.3389/fimmu.2017.01514 ↗
35. 10.1038/s41577-018-0058-710.1038/s41577-018-0058-7 ↗
36. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
37. 10.1016/j.prp.2019.15269110.1016/j.prp.2019.152691 ↗
38. 10.1186/s12935-018-0585-010.1186/s12935-018-0585-0 ↗
39. 10.3389/fimmu.2012.0027410.3389/fimmu.2012.00274 ↗
40. 10.1182/blood-2001-11-001710.1182/blood-2001-11-0017 ↗
41. 10.1084/jem.181.2.77510.1084/jem.181.2.775 ↗
42. 10.1016/j.immuni.2023.05.01110.1016/j.immuni.2023.05.011 ↗
43. 10.18632/oncotarget.1056110.18632/oncotarget.10561 ↗
44. 10.3390/ijms2213699510.3390/ijms22136995 ↗
45. 10.1016/j.biopha.2024.11693010.1016/j.biopha.2024.116930 ↗
46. 10.1016/0167-5699(94)90193-710.1016/0167-5699(94)90193-7 ↗
47. 10.1016/j.immuni.2020.04.01410.1016/j.immuni.2020.04.014 ↗
48. 10.1128/MCB.00456-1010.1128/MCB.00456-10 ↗
49. 10.1038/cddis.2015.16210.1038/cddis.2015.162 ↗
50. 10.1182/blood-2008-12-19579210.1182/blood-2008-12-195792 ↗
51. 10.1002/adfm.20230547310.1002/adfm.202305473 ↗